Immunome reports Q3 EPS (65c), consensus (54c)

As of September 30, 2025, cash and cash equivalents totaled $272.6 million, including net proceeds of $44.9 million from two transactions under its at-the-market equity offering program. Immunome (IMNM) expects its current cash position to fund operations into 2027. “Immunome’s pipeline continues to advance,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “We anticipate the release of topline data for the RINGSIDE trial of varegacestat before the end of this year, to be followed by an NDA submission if warranted. I am particularly pleased to share that we have observed objective responses at multiple dose levels in B-cell lymphoma patients treated with IM-1021. The clinical activity and safety we’ve seen underscore the potential of HC74, our proprietary TOP1 inhibitor ADC payload. We plan to present initial data for that program in 2026.”